cagrisema cagrilintide semaglutide phase 3 obesity Cagrilintide–semaglutide (CagriSema) as an add-on to basal insulin in adults with type 2 diabetes (REIMAGINE 3): a randomised, double-blind, placebo-controlled, multicentre, study Cagrilintide and Semaglutide: CagriSema Weight

A 2015 Cell Metabolism study that first characterized MOTS-c as a mitochondria-derived regulator of metabolic homeostasis capable of reducing obesity and insulin resistance in animal models was foundational in establishing this peptide class

If the developer has received a complete response letter or an FDA request for additional information, the effective approval date shifts accordingly

Gastric bypass patients are at risk for micronutrient deficiencies which lead to in the short term, leading to impaired healing from the surgery, and in the long term, major medical issues such as anemia, scurvy, beriberi, osteoporosis and other conditions

Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma